within Pharmacolibrary.Drugs.ATC.M;

model M05BX07
  extends Pharmacokinetic.Models.PK_1C(
    weight         = 70,
    F              = 1,
    Cl             = 0.0004116666666666667,
    adminDuration  = 600,
    adminMass      = 15 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.008400000000000001,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>M05BX07</td></tr><td>route:</td><td>subcutaneous</td></tr><tr><td>n-compartments</td><td>1</td></tr></table><p>Vosoritide is a recombinant human C-type natriuretic peptide (CNP) analogue indicated for the treatment of achondroplasia in patients who are aged 2 years and older with open epiphyses. It is approved for use in several regions, including the US and EU. Vosoritide acts as a growth modulator by binding to natriuretic peptide receptor NPR-B (NPR2), stimulating endochondral bone growth.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reported in pediatric subjects (age 5-14 years) with achondroplasia after daily subcutaneous administration of vosoritide. The model assumes a one-compartment disposition.</p><h4>References</h4><ol><li><p>Chan, ML, et al., &amp; Henshaw, J (2022). Pharmacokinetics and Exposure-Response of Vosoritide in Children with Achondroplasia. <i>Clinical pharmacokinetics</i> 61(2) 263–280. DOI:<a href=\"https://doi.org/10.1007/s40262-021-01059-1\">10.1007/s40262-021-01059-1</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/34431071/\">https://pubmed.ncbi.nlm.nih.gov/34431071</a></p></li><li><p>Galetaki, D, et al., &amp; Dauber, A (2024). Phase 2 Trial of Vosoritide Use in Patients with Hypochondroplasia: A Pharmacokinetic/Pharmacodynamic Analysis. <i>Hormone research in paediatrics</i> None 1–7. DOI:<a href=\"https://doi.org/10.1159/000542102\">10.1159/000542102</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/39427650/\">https://pubmed.ncbi.nlm.nih.gov/39427650</a></p></li><li><p>Schneider, EL, et al., &amp; Santi, DV (2022). A long-acting C-natriuretic peptide for achondroplasia. <i>Proceedings of the National Academy of Sciences of the United States of America</i> 119(30) e2201067119–None. DOI:<a href=\"https://doi.org/10.1073/pnas.2201067119\">10.1073/pnas.2201067119</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/35858423/\">https://pubmed.ncbi.nlm.nih.gov/35858423</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end M05BX07;
